Drug intelligence / Profile preview

Tulou Penyanqing

Development stage: Unknown
Lead developer: Guangzhou Lanyun Pharmaceutical Research
Modality: Small Molecules
Administration: Oral

Overview

Tulou Penyanqing is a Traditional Chinese Medicine (TCM) candidate developed by Guangzhou Lanyun Pharmaceutical Research Co., Ltd. for the treatment of sequelae of pelvic inflammatory disease (PID). Formulated as an oral tablet, it is designed to alleviate chronic pelvic pain and inflammation by promoting blood circulation, resolving blood stasis, and clearing heat and toxins. The drug has been evaluated in Phase II clinical trials in China, targeting the long-term complications of PID, such as chronic pelvic pain and tissue adhesions, which often persist after the resolution of an acute infection.

Brand names: Tulou Penyanqing
Other names: Tulou Penyanqing TabletsTulou Penyanqing Pian土楼盆炎清片

Beyond the preview

Go deeper on Tulou Penyanqing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tulou Penyanqing.

Explore the full profile